Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
APL-5125 in Locally Advanced Malignant Solid Neoplasm: NCT06399757 Clinical Landscape Report 2026
15 October 2026
NCT06399757 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Itraconazole in Ovarian Cancer: NCT06400472 Clinical Landscape Report 2026
15 October 2026
NCT06400472 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Capecitabine in Breast Cancer: CTRI/2024/05/066872 Clinical Landscape Report 2026
15 October 2026
CTRI/2024/05/066872 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT06404736 Clinical Landscape Report 2026
15 October 2026
NCT06404736 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Triple Negative Breast Cancer: NCT06407310 Clinical Landscape Report 2026
15 October 2026
NCT06407310 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma, IDH-Wildtype: NCT06410248 Clinical Landscape Report 2026
15 October 2026
NCT06410248 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
REGN-10597 in Advanced Malignant Solid Neoplasm: NCT06413680 Clinical Landscape Report 2026
15 October 2026
NCT06413680 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Pumitamig in Triple Negative Breast Cancer: NCT06419621 Clinical Landscape Report 2026
15 October 2026
NCT06419621 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma, IDH-Wildtype: NCT06419946 Clinical Landscape Report 2026
15 October 2026
NCT06419946 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cadonilimab in Renal Cell Carcinoma: NCT06427057 Clinical Landscape Report 2026
15 October 2026
NCT06427057 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitoquinone mesylate in Amyotrophic Lateral Sclerosis: NCT06429059 Clinical Landscape Report 2026
15 October 2026
NCT06429059 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Doxorubicin Hydrochloride liposomal in Locally Advanced Unresectable Breast Carcinoma: NCT06434064 Clinical Landscape Report 2026
15 October 2026
NCT06434064 clinical landscape for Locally Advanced Unresectable Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developm…